Gay Kathryn, Robicsek Ari, Strahilevitz Jacob, Park Chi Hye, Jacoby George, Barrett Timothy J, Medalla Felicita, Chiller Tom M, Hooper David C
Atlanta Research and Education Foundation, Atlanta, GA, USA.
Clin Infect Dis. 2006 Aug 1;43(3):297-304. doi: 10.1086/505397. Epub 2006 Jun 20.
Serious infections with Salmonella species are often treated with fluoroquinolones or extended-spectrum beta-lactams. Increasingly recognized in Enterobacteriaceae, plasmid-mediated quinolone resistance is encoded by qnr genes. Here, we report the presence of qnr variants in human isolates of non-Typhi serotypes of Salmonella enterica (hereafter referred to as non-Typhi Salmonella) from the United States National Antimicrobial Resistance Monitoring System for Enteric Bacteria.
All non-Typhi Salmonella specimens from the United States National Antimicrobial Resistance Monitoring System for Enteric Bacteria collected from 1996 to 2003 with ciprofloxacin minimum inhibitory concentrations > or = 0.06 microg/mL (233 specimens) and a subset with minimum inhibitory concentrations < or = 0.03 microg/mL (102 specimens) were screened for all known qnr genes (A, B, and S) by polymerase chain reaction. For isolates with positive results, qnr and quinolone resistance-determining region sequences were determined. Plasmids containing qnr genes were characterized by conjugation or transformation.
Conjugative plasmids harboring qnrB variants were detected in 7 Salmonella enterica serotype Berta isolates and 1 Salmonella enterica serotype Mbandaka isolate. The S. Mbandaka plasmid also had an extended-spectrum beta -lactamase. Variants of qnrS on nonconjugative plasmids were detected in isolates of Salmonella enterica serotype Anatum and Salmonella enterica serotype Bovismorbificans.
Plasmid-mediated quinolone resistance appears to be widely distributed, though it is still uncommon in non-Typhi Salmonella isolates from the United States, including strains that are quinolone susceptible by the criteria of the Clinical and Laboratory Standards Institute (formerly the National Committee for Clinical Laboratory Standards). The presence of this gene in non-Typhi Salmonella that causes infection in humans suggests potential for spread through the food supply, which is a public health concern.
沙门氏菌属的严重感染通常用氟喹诺酮类药物或广谱β-内酰胺类药物治疗。质粒介导的喹诺酮耐药性在肠杆菌科中越来越受到关注,它由qnr基因编码。在此,我们报告在美国国家肠道细菌抗菌药物耐药性监测系统中,从人类分离出的非伤寒血清型肠炎沙门氏菌(以下简称非伤寒沙门氏菌)中存在qnr变体。
对1996年至2003年从美国国家肠道细菌抗菌药物耐药性监测系统收集的所有非伤寒沙门氏菌标本进行检测,这些标本的环丙沙星最低抑菌浓度≥0.06μg/mL(233份标本),以及最低抑菌浓度≤0.03μg/mL的一个子集(102份标本),通过聚合酶链反应筛选所有已知的qnr基因(A、B和S)。对于结果呈阳性的分离株,测定qnr和喹诺酮耐药性决定区序列。含有qnr基因的质粒通过接合或转化进行鉴定。
在7株肠炎沙门氏菌贝塔血清型分离株和1株肠炎沙门氏菌班达卡血清型分离株中检测到携带qnrB变体的接合质粒。班达卡血清型沙门氏菌的质粒还具有一种广谱β-内酰胺酶。在肠炎沙门氏菌阿纳姆血清型和肠炎沙门氏菌牛病血清型的分离株中检测到非接合质粒上的qnrS变体。
质粒介导的喹诺酮耐药性似乎广泛存在,尽管在美国非伤寒沙门氏菌分离株中仍然不常见,包括那些根据临床和实验室标准研究所(原国家临床实验室标准委员会)标准对喹诺酮敏感的菌株。这种基因在引起人类感染的非伤寒沙门氏菌中的存在表明有可能通过食物供应传播,这是一个公共卫生问题。